Meet the Investors

Michel de Baar | Executive Director, BD&L - Infectious Diseases & Vaccines, CardioMetabolic- and Immunology Diseases | MSD

Michel is a business development and licensing professional with experience in all steps of business development and transaction processes within the global pharmaceutical, biotechnology and diagnostics industries. Michel is a scientist by training, and in addition to a PhD in molecular virology from the University of Amsterdam, he also holds an MBA from Rotterdam School of Management. Michel joined the Global Business Development & Licensing (BD&L) team of MSD back in 2016. The goal for the London-based BD&L team is to augment the pipeline for MSD through Search, Evaluation and Transaction of opportunities in Europe and the Middle East.

About MSD

A Legacy of Innovation
MSD has a strong history of success in translating cutting-edge research into life-saving medical breakthroughs. Our scientific advances have made a difference in the lives of millions of patients worldwide. From MSD’s development of the first measles and mumps vaccines to treatments for cancer and diabetes, we are an industry leader in bringing forth innovative new medicines. We operate in more than 140 countries and had sales of more than $60 billion in 2023.

Find out more on how to partner with MSD on https:///www.msdlicensing.com